Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis. - Wikidata - wikimedia - TriplyDB

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

http://www.wikidata.org/entity/Q37365476

about

Regulatory effects of C5a on IL-17A, IL-17F, and IL-23 CD318 is a ligand for CD6.CD6 as a potential target for treating multiple sclerosis Beyond the Role of CD55 as a Complement Component.Complement After Trauma: Suturing Innate and Adaptive Immunity

P2860

Q36518989-65FE5ABF-57FD-4DE5-BD6C-0BE694FE7226 Q41476987-CF61606F-1BFD-4736-9723-BD4A1150A5BF Q42177117-74948F0A-715D-45CD-AACB-DC2F4A5832C4 Q50338802-618E214D-5E92-485D-AE95-AE030B710B7D Q57492399-E9C9C289-689F-45ED-B4F6-6A822569DAAE

P2860

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

http://www.wikidata.org/entity/Q37365476

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

@en

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

@nl

type

label

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

@en

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

@nl

prefLabel

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

@en

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

@nl

P1433

Q37365476-C7DBCF8D-4E25-4A1F-9F04-36DACEF65CCA

P1476

Q37365476-378B1257-AA1E-4C71-A181-036CDA15E791

P2093

Q37365476-18D55BD6-C018-49D1-B804-B69746C272E4

Q37365476-6EA035F7-006E-4F91-A314-CC9710C160A7

Q37365476-9AA933C8-CD78-4DFD-89A8-15606A906FB7

Q37365476-A2939DEC-B2B2-4825-9948-D4EB73E7F5DB

Q37365476-E4942A0F-9378-4D43-B36B-820B540527D5

P2860

Q37365476-024E2BC3-AF8F-44FF-B383-54A65479CB68

Q37365476-05D52651-D45D-48CB-AA0B-68FA2E7F0B08

Q37365476-37FD1662-03B6-4E64-ACFF-605A273566CF

Q37365476-498C9372-D397-41B5-B296-82ED2CE1D7B1

Q37365476-49FC8B9A-2086-4CA9-BE77-9FE6677398F2

Q37365476-4E538F87-A317-4358-A870-155A489AC831

Q37365476-5652AE70-358D-4E9D-8151-4C8052418679

Q37365476-61ED5A3D-1158-4533-AAB0-55DF2797F5DB

Q37365476-67CD39C7-2E19-4316-A859-107224C7666D

Q37365476-72A648CE-3689-4E7E-8931-59F6573819F3

P304

Q37365476-C8E74305-F12D-4A21-BDD9-8FC14C3A0B57

P31

Q37365476-46069650-ABEA-4BBD-A5AF-CAD06BC58A48

P356

Q37365476-18A7120D-98DB-4CD7-9A30-36388CC24CC7

P433

Q37365476-B83DC66E-FDDE-458B-8413-ACF22E254E94

P478

Q37365476-E90786ED-8BA8-4E81-822C-97CF4DEC1059

P577

Q37365476-DDF3A95F-388F-4800-8EF0-6B7913AA9F42

P5875

Q37365476-E20B621E-A66A-4671-8E8B-6B40803A6634

P698

Q37365476-D9673758-C2E1-44A8-8E74-F731728C9829

P921

Q37365476-B7C178B2-B0D4-4EBB-9C69-55A8DCA1CDA9

P932

Q37365476-1210B484-EF29-4253-A288-EC1E167C5814

P356

J.MOLIMM.2009.07.003

P1433

Molecular Immunology

P1476

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

@en

P2093

Danping Huang

http://www.w3.org/2001/XMLSchema#string

Feng Lin

http://www.w3.org/2001/XMLSchema#string

Hong Bu

http://www.w3.org/2001/XMLSchema#string

Kristine Nacion

http://www.w3.org/2001/XMLSchema#string

Qing Li

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype

Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting

Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes

Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells.

Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms

Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice

Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells

Decay-accelerating factor modulates induction of T cell immunity

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.

IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production

P304

2885-2891

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLIMM.2009.07.003

http://www.w3.org/2001/XMLSchema#string

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26722839

http://www.w3.org/2001/XMLSchema#string

P698

19660813

http://www.w3.org/2001/XMLSchema#string

P921

experimental autoimmune encephalomyelitis

P932

2753188

http://www.w3.org/2001/XMLSchema#string